ceftobiprole
Trade name: Zevtera
Approved
Apr 3, 2024
Ceftobiprole, sold under the brand name Zevtera among others, is a fifth-generation cephalosporin antibacterial used for the treatment of hospital-acquired pneumonia and community-acquired pneumonia. It is marketed by Basilea Pharmaceutica under the brand names Zevtera and Mabelio. Like other cephalosporins, ceftobiprole exerts its antibacterial activity by binding to important penicillin-binding proteins and inhibiting their transpeptidase activity which is essential for the synthesis of bacterial cell walls. Ceftobiprole has high affinity for penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus strains and retains its activity against strains that express divergent mecA gene homologues. Ceftobiprole also binds to penicillin-binding protein 2b in Streptococcus pneumoniae (penicillin-intermediate), to penicillin-binding protein 2x in Streptococcus pneumoniae (penicillin-resistant), and to penicillin-binding protein 5 in Enterococcus faecalis. — Wikipedia
Clinical trial activity
22 trials · 8 clinical orgs · 1 marketing orgs
Earliest trial started Oct 1, 2004 (NCT00228982)
Timeline
2000s
- Jan 1, 2004
Basilea Pharmaceutica — Earliest Phase 3 Sponsor(trial)
- Jan 1, 2007
Basilea Pharmaceutica — Earliest Phase 1 Sponsor(trial)
- Jan 1, 2007
Basilea Pharmaceutica — Earliest Phase 2 Sponsor(trial)
2020s
- Apr 3, 2024
Basilea Pharmaceutica — Earliest FDA Approval
- Apr 3, 2024
Basilea Pharmaceutica — NDA Organization
Indications
Approved for
Studied for
- Anti-Infective Agents · Phase 1
- Bacteremia · Phase 2
- Bacterial Infections · Phase 3
- Cephalosporins · Phase 1
- Cerebral Ventriculitis · Phase 2
- Community-Acquired Infections · Phase 3
- Drug Resistance · Phase 1
- Fever · Phase 3
- General Surgery · Phase 1
- Gram-Positive Bacterial Infections · Phase 3
- Healthcare-Associated Pneumonia · Phase 3
- Inflammation · Phase 2
- Intensive Care Units · Phase 1
- Meningitis · Phase 2
- Neonatal Sepsis · Phase 3
- Neutropenia · Phase 3
- Obesity · Phase 1
- Pneumonia · Phase 3
- Pneumonia, Ventilator-Associated · Phase 1
- Pseudomonas Infections · Phase 3
- Skin Diseases, Bacterial · Phase 3
- Skin Diseases, Infectious · Phase 3
- Staphylococcal Infections · Phase 3
- Staphylococcal Skin Infections · Phase 3
- Streptococcal Infections · Phase 1
Mechanism of action
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
Active against Staphylococcus aureus (including MRSA), Streptococcus pneumoniae, Escherichia coli, and Klebsiella pneumoniae and Haemophilus influenzae. Binds bacterial PBPs. In gram-positive bacteria, binds PBP2a incl. divergent mecA homologues (mecC or mecALGA251), PBP2a and PBP2x from penicillin-intermediate Streptococcus pneumoniae and binds to PBP5 in Enterococcus faecalis.
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
- Penicillin-binding protein 4INHIBITOR
Penicillin-binding protein 4 inhibitor
- Penicillin-binding protein 2INHIBITOR
Penicillin-binding protein 2 inhibitor
- Penicillin-binding protein 1INHIBITOR
Penicillin-binding protein 1 inhibitor
- Penicillin-binding protein 3INHIBITOR
Penicillin-binding protein 3 inhibitor
- MecAINHIBITOR
MecA inhibitor
- Penicillin-binding proteinINHIBITOR
Penicillin-binding protein inhibitor
- Penicillin-binding protein 1INHIBITOR
pbp1 inhibitor
Approval history
- approvedPriority reviewFast trackApr 3, 2024
Chemistry & pharmacology
SMILES
Cc1oc(=O)oc1COC(=O)N1CC[C@@H](N2CC/C(=C\C3=C(C(=O)O)N4C(=O)[C@@H](NC(=O)/C(=N/O)c5nsc(N)n5)[C@H]4SC3)C2=O)C1- Mol. weight
- 690.67 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaCeftobiprole ↗
- ChEMBLCHEMBL520642 ↗
- ChEMBLCHEMBL4297101 ↗
- ChEMBLCHEMBL1652606 ↗
Also known as
- bal5788
- bal5788
- bal 5788
- bal-5788
- bal-5788
- bal-5788
- bal5788-001
- bal5788-001
- bal9141
- bal9141
- bal 9141
- bal 9141
- bal-9141
- bal 9141-000
- bal9141-000
- bal9141-000
- ceftobiprole
- ceftobiprole
- ceftobiprole
- ceftobiprole
- ceftobiprole
- ceftobiprole
- ceftobiprole medocaril
- ceftobiprole medocaril
- ceftobiprole medocaril
- ceftobiprole medocaril
- ceftobiprole medocaril
- ceftobiprole medocaril
- ceftobiprole medocaril
- ceftobiprole medocaril
- ceftobiprole medocaril
- ceftobiprole medocaril free acid
- ceftobiprole medocaril (inn)
- ceftobiprole medocaril sodium
- ceftobiprole medocaril sodium
- ro-639141
- ro-639141
- ro 65-5788
- ro-655788
- ro-655788
- zeftera
- zevtera
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05856227 | Phase 3 | Aug 6, 2023 | Basilea Pharmaceutica |
| NCT04171674 | N/A | Nov 30, 2019 | Centre Hospitalier Universitaire de Nīmes, University of Bordeaux, University of Lyon, University of Nimes |
| NCT03317093 | Phase 2 | Mar 29, 2018 | University of Burgundy |
| NCT03439124 | Phase 3 | Nov 27, 2017 | Basilea Pharmaceutica |
| NCT03137173 | Phase 3 | Jun 1, 2017 | Basilea Pharmaceutica, Department of Health and Human Services |
| NCT03138733 | Phase 3 | Jun 1, 2017 | Basilea Pharmaceutica, Department of Health and Human Services |
| NCT02527681 | Phase 1 | Aug 1, 2014 | Basilea Pharmaceutica |
| NCT00771524 | Phase 1 | Apr 1, 2009 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT00965042 | Phase 1 | Apr 1, 2009 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT00770978 | Phase 1 | Nov 1, 2008 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT00771719 | Phase 1 | Oct 1, 2008 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT00529282 | Phase 3 | Oct 1, 2007 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT01026558 | Phase 1 | Aug 1, 2007 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT01026636 | Phase 1 | Aug 1, 2007 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT00505258 | Phase 2 | Jul 19, 2007 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT01026740 | Phase 1 | Jun 1, 2007 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT01030731 | Phase 1 | May 1, 2007 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT00326287 | Phase 3 | Jun 1, 2006 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT00229008 | Phase 3 | Nov 1, 2005 | Basilea Pharmaceutica, Johnson and Johnson |
| NCT00210899 | Phase 3 | Sep 1, 2005 | Basilea Pharmaceutica, Johnson and Johnson |
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Basilea Pharmaceutica | For profit | 20 | 20 | 3 | 2004 |
| Johnson and Johnson | For profit | 15 | 0 | 3 | 2004 |
| Department of Health and Human Services | Government | 2 | 0 | 1 | 2017 |
| Centre Hospitalier Universitaire de Nīmes | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Bordeaux | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Burgundy | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Lyon | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Nimes | Academic/Hospital | 1 | 0 | 1 | 2019 |
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Basilea Pharmaceutica | For profit | NDA | Apr 3, 2024 |